Back to Search
Start Over
Effect of Empagliflozin on Cardiac Function, Adiposity, and Diffuse Fibrosis in Patients with Type 2 Diabetes Mellitus
- Source :
- Scientific Reports, Scientific Reports, Vol 9, Iss 1, Pp 1-9 (2019)
- Publication Year :
- 2019
- Publisher :
- Springer Science and Business Media LLC, 2019.
-
Abstract
- Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, significantly improves cardiovascular outcomes in diabetic patients; however, the mechanism is unclear. We hypothesized that empagliflozin might have beneficial effects on cardiac function, structure, adiposity, and myocardial diffuse fibrosis. This prospective study enrolled 35 patients (48.6% men, age 63.5 ± 9.7 years) with type 2 diabetes mellitus (T2DM) from June 1, 2017, to November 31, 2018. The patients received an SGLT2 inhibitor (empagliflozin 25 or 12.5 mg/d) for 6 months in addition to stable oral hypoglycaemic treatment. All patients underwent cardiac magnetic resonance imaging (CMRI) before and after empagliflozin treatment. Left ventricular (LV) function and structure were quantified using cine CMRI. Cardiac adiposity was defined based on pericardial fat and intracardiac triglyceride contents, whereas myocardial diffuse fibrosis was indicated by extracellular volume (ECV). The statistical significance of parameter changes was assessed using paired t-test and stepwise multiple linear regression. There were no significant differences in LV function and structure changes. Cardiac adiposity and diffuse fibrosis indices were also not different before and after empagliflozin treatment. Concerning clinical parameters, only a significant decrease in systolic blood pressure (by 6.4 mmHg) was observed (p = 0.013). Stepwise multiple linear regression revealed that worse baseline MRI parameters were associated with better improvements. Intracardiac triglyceride content decrease was inversely associated with baseline intracardiac triglyceride content (p
- Subjects :
- Male
Cardiac function curve
medicine.medical_specialty
Heart Ventricles
lcsh:Medicine
030209 endocrinology & metabolism
030204 cardiovascular system & hematology
Article
03 medical and health sciences
0302 clinical medicine
Glucosides
Cardiac magnetic resonance imaging
Fibrosis
Internal medicine
Diabetes mellitus
Empagliflozin
medicine
Humans
Benzhydryl Compounds
lcsh:Science
Prospective cohort study
Triglycerides
Adiposity
Multidisciplinary
Ejection fraction
medicine.diagnostic_test
business.industry
Myocardium
lcsh:R
Type 2 diabetes
Middle Aged
medicine.disease
Blood pressure
Diabetes Mellitus, Type 2
Heart Function Tests
Multivariate Analysis
Linear Models
Cardiology
lcsh:Q
Female
Cardiomyopathies
business
Subjects
Details
- ISSN :
- 20452322
- Volume :
- 9
- Database :
- OpenAIRE
- Journal :
- Scientific Reports
- Accession number :
- edsair.doi.dedup.....529f08adf704836b920c0e2225daa48c